UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 12, 2019
Alector, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-38792 |
|
82-2933343 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer |
131 Oyster Point Blvd. Suite 600
South San Francisco, California 94080
(Address of principal executive offices, including zip code)
(415) 231-5660
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
|
Common Stock |
ALEC |
The NASDAQ Global Select Market |
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2019, Alector, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2019. A press release announcing these results, which is attached hereto as Exhibit 99.1, is incorporated herein by reference.
All of the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits
99.1Press Release dated August 12, 2019
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ALECTOR, INC. |
|
|
|
|
|
|
|
Date: August 12, 2019 |
|
By: |
/s/ Arnon Rosenthal |
|
|
|
|
Arnon Rosenthal, Ph.D. |
|
|
|
|
Co-Founder and Chief Executive Officer |
Exhibit 99.1
Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results
|
|
- |
Completed planned enrollment of AL001 Phase 1b trial and demonstrated proof-of-mechanism in Frontotemporal Dementia patients |
|
|
- |
AL101 granted Orphan Drug Designation from U.S. FDA |
|
|
- |
Ended the quarter with $411 million in cash, cash equivalents and marketable securities |
SOUTH SAN FRANCISCO, Calif. – August 12, 2019 – Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced company highlights and financial results for the second quarter of 2019.
“We are continuing to make substantial progress in our efforts to bring novel disease-modifying treatments to patients suffering from neurodegenerative diseases,” said Arnon Rosenthal, Ph.D., chief executive officer of Alector. “We are very encouraged by the recent data from our AL001 program in patients suffering from frontotemporal dementia. In addition, with the continued progress of our AL002 and AL003 programs targeting Alzheimer’s disease and our fourth program, AL101, moving towards the clinic, we believe we have the opportunity to transform treatment for patients suffering from these devastating diseases.”
Recent Business Highlights
|
|
● |
Data Presented at AAIC Demonstrate AL001 Reverses Progranulin Deficiency in FTD patients – In July 2019, Alector reported initial positive data with its product candidate, AL001, in FTD patients with a specific mutation in the progranulin (PGRN) gene. Data showed that AL001 elicited a dose-dependent increase in PGRN levels, restoring the level of PGRN in the plasma and in the CSF back to the normal range. |
|
|
● |
AL001 Phase 1b Enrollment Completed – In July 2019, Alector completed the planned enrollment of its Phase 1b clinical trial in FTD-GRN patients. The Company expects to immediately begin the Phase 2 study in FTD-GRN patients in the second half of 2019. |
|
|
● |
AL101 Granted Orphan Drug Designation from U.S. FDA – In July 2019, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to AL101, the company’s second program for the treatment of patients with FTD. Alector will be developing AL101 for FTD, as well as specific subsets of patients suffering from other neurological disorders. |
Second Quarter 2019 Financial Results
Revenue. Collaboration revenue for the second quarter of 2019 was $6.9 million compared to $7.1 million for the same period in 2018. The decrease was driven primarily by lower expenses based on the scheduled timing of production with contract manufacturers that resulted in less revenue recognized under Alector’s collaboration agreement with AbbVie for the current period.
R&D Expenses. Total research and development expenses for the second quarter of 2019 were $25.6 million compared to $16.8 million for the same period in 2018. The increase was driven by higher personnel-related expenses as headcount grew to support the advancement of the clinical and preclinical programs, increased expenditures related to the clinical trials, increased laboratory expenses for the development of our pipeline, and increased facilities and other unallocated research and development expenses to support the growth of the business.
G&A Expenses. Total general and administrative expenses for the second quarter of 2019 were $8.4 million compared to $2.5 million for the same period in 2018. This increase was primarily due to higher personnel-related expenses, increased facilities and general overhead expenses, and increased consulting expenses related to information technology, accounting, legal, human resources, and other administrative functions to support the growth of the business.
Net Loss. For the second quarter of 2019, Alector reported a net loss of $24.6 million, compared to a net loss of $11.1 million for the same period in 2018.
Cash Position. Cash, cash equivalents, and marketable securities were $410.9 million as of June 30, 2019.
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our beliefs and assumptions and on information currently available to us on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company’s financial condition and results of operations, and plans for the Company’s product candidates, clinical studies and anticipated regulatory and development milestones. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports Alector files with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q that is being filed with the Securities and Exchange Commission (“SEC”). Copies of reports filed with the SEC are posted on Alector’s website and are available from Alector without charge.
Selected Consolidated Balance Sheet Data
(in thousands)
(unaudited)
|
|
|
June 30, |
|
December 31, |
|
||||||
|
|
|
2019 |
|
|
2018 |
|
|
|
|||
|
|
|
|
|||||||||
|
Cash, cash equivalents, and marketable securities |
|
$ |
410,933 |
|
|
$ |
290,408 |
|
|
|
|
|
Total assets |
|
|
477,251 |
|
|
|
308,359 |
|
|
|
|
|
Total current liabilities (excluding deferred revenue) |
|
|
26,231 |
|
|
|
13,043 |
|
|
|
|
|
Deferred revenue (including current portion) |
|
|
162,098 |
|
|
|
174,620 |
|
|
|
|
|
Total liabilities |
|
|
231,535 |
|
|
|
195,237 |
|
|
|
|
|
Convertible preferred stock (1) |
|
|
— |
|
|
|
210,520 |
|
|
|
|
|
Total stockholders’ equity |
|
|
245,716 |
|
|
|
(97,398 |
) |
|
|
|
(1) Upon the closing of our IPO in February 2019, all of the outstanding shares of our convertible
preferred stock converted into 45,374,836 shares of common stock.
Consolidated Statement of Operations Data
(in thousands, except share and per share data)
(unaudited)
|
|
|
|
Three Months Ended June 30, |
Six Months Ended June 30, |
|
||||||||||||||||||||||||||||
|
|
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||||||||||||||||||
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Collaboration revenue |
|
$ |
6,917 |
|
|
$ |
7,109 |
|
|
$ |
12,522 |
|
|
$ |
11,860 |
|
|||||||||||||||||
|
Grant revenue |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
169 |
|
|||||||||||||||||
|
Total revenue |
|
|
6,917 |
|
|
|
7,109 |
|
|
|
12,522 |
|
|
|
12,029 |
|
|||||||||||||||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Research and development |
|
|
25,640 |
|
|
|
16,818 |
|
|
|
46,247 |
|
|
|
28,542 |
|
|||||||||||||||||
|
General and administrative |
|
|
8,429 |
|
|
|
2,522 |
|
|
|
14,188 |
|
|
|
4,943 |
|
|||||||||||||||||
|
Total operating expenses |
|
|
34,069 |
|
|
|
19,340 |
|
|
|
60,435 |
|
|
|
33,485 |
|
|||||||||||||||||
|
Loss from operations |
|
|
(27,152 |
) |
|
|
(12,231 |
) |
|
|
(47,913 |
) |
|
|
(21,456 |
) |
|||||||||||||||||
|
Other income, net |
|
|
2,592 |
|
|
|
1,110 |
|
|
|
4,793 |
|
|
|
1,898 |
|
|||||||||||||||||
|
Net loss |
|
$ |
(24,560 |
) |
|
$ |
(11,121 |
) |
|
$ |
(43,120 |
) |
|
$ |
(19,558 |
) |
|||||||||||||||||
|
Net loss per share, basic and diluted |
|
$ |
(0.36 |
) |
|
$ |
(1.00 |
) |
|
$ |
(0.77 |
) |
|
$ |
(1.78 |
) |
|||||||||||||||||
|
Shares used in computing net loss per share, basic and diluted |
|
|
67,327,975 |
|
|
|
11,157,024 |
|
|
|
55,643,352 |
|
|
|
11,008,568 |
|
|||||||||||||||||
Contacts
Media:
1AB
Dan Budwick, 973-271-6085
dan@1abmedia.com
or
Investors:
Alector, Inc.
ir@alector.com